A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Needle, MD
AVEO Pharmaceuticals, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Antwerp, Belgium
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Bordeaux, France
- Facility name not stated
Caen, France
- Facility name not stated
Lyon, France
- Facility name not stated
Paris, France
- Facility name not stated
Berlin, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Hanover, Germany
- Facility name not stated
Heidelberg, Germany
- Facility name not stated
Munich, Germany
- Facility name not stated
Aviano, Italy
- Facility name not stated
Pavia, Italy
- Facility name not stated
Rome, Italy
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Pamplona, Spain
- Facility name not stated
Valencia, Spain
- Facility name not stated
Glasgow, Scotland, United Kingdom
- Facility name not stated
Swansea, Wales, United Kingdom
- Facility name not stated
Cambridge, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Albany, Georgia, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Shreveport, Louisiana, United States
- Facility name not stated
Worcester, Massachusetts, United States
- Facility name not stated
Minneapolis, Minnesota, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Columbus, Ohio, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Charleston, South Carolina, United States
- Facility name not stated
Myrtle Beach, South Carolina, United States
- Facility name not stated
San Antonio, Texas, United States
- Facility name not stated
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2012
- Primary completion
- 31 Jan 2014
- Completion
- 31 Jan 2014
- Last update posted
- 27 Oct 2020
- Registered enrollment
- 58
- Registry id
- NCT01673386
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.